Nutrient mixture improves memory in patients with early Alzheimer's
A graphic depicting a synapse, a connection between brain cells. Graphic: Christine Daniloff
A clinical trial of an Alzheimers disease treatment developed at MIT has found that the nutrient cocktail can improve memory in patients with early Alzheimers. The results confirm and expand the findings of an earlier trial of the nutritional supplement, which is designed to promote new connections between brain cells.
Alzheimers patients gradually lose those connections, known as synapses, leading to memory loss and other cognitive impairments. The supplement mixture, known as Souvenaid, appears to stimulate growth of new synapses, says Richard Wurtman, a professor emeritus of brain and cognitive sciences at MIT who invented the nutrient mixture.
You want to improve the numbers of synapses, not by slowing their degradation though of course youd love to do that too but rather by increasing the formation of the synapses, Wurtman says.
To do that, Wurtman came up with a mixture of three naturally occurring dietary compounds: choline, uridine and the omega-3 fatty acid DHA. Choline can be found in meats, nuts and eggs, and omega-3 fatty acids are found in a variety of sources, including fish, eggs, flaxseed and meat from grass-fed animals. Uridine is produced by the liver and kidney, and is present in some foods as a component of RNA.
These nutrients are precursors to the lipid molecules that, along with specific proteins, make up brain-cell membranes, which form synapses. To be effective, all three precursors must be administered together.
Results of the clinical trial, conducted in Europe, appear in the July 10 online edition of the Journal of Alzheimers Disease. The new findings are encouraging because very few clinical trials have produced consistent improvement in Alzheimers patients, says Jeffrey Cummings, director of the Cleveland Clinics Lou Ruvo Center for Brain Health.
Memory loss is the central characteristic of Alzheimers, so something that improves memory would be of great interest, says Cummings, who was not part of the research team.
Plans for commercial release of the supplement are not finalized, according to Nutricia, the company testing and marketing Souvenaid, but it will likely be available in Europe first. Nutricia is the specialized health care division of the food company Danone, known as Dannon in the United States.
Wurtman first came up with the idea of targeting synapse loss to combat Alzheimers about 10 years ago. In animal studies, he showed that his dietary cocktail boosted the number of dendritic spines, or small outcroppings of neural membranes, found in brain cells. These spines are necessary to form new synapses between neurons.
Following the successful animal studies, Philip Scheltens, director of the Alzheimer Center at VU University Medical Center in Amsterdam, led a clinical trial in Europe involving 225 patients with mild Alzheimers. The patients drank Souvenaid or a control beverage daily for three months.
That study, first reported in 2008, found that 40 percent of patients who consumed the drink improved in a test of verbal memory, while 24 percent of patients who received the control drink improved their performance.
The new study, performed in several European countries and overseen by Scheltens as principal investigator, followed 259 patients for six months. Patients, whether taking Souvenaid or a placebo, improved their verbal-memory performance for the first three months, but the placebo patients deteriorated during the following three months, while the Souvenaid patients continued to improve. For this trial, the researchers used more comprehensive memory tests taken from the neuropsychological test battery, often used to assess Alzheimers patients in clinical research.
Patients showed a very high compliance rate: About 97 percent of the patients followed the regimen throughout the study, and no serious side effects were seen.
Both clinical trials were sponsored by Nutricia. MIT has patented the mixture of nutrients used in the study, and Nutricia holds the exclusive license on the patent.
In the new study, the researchers used electroencephalography (EEG) to measure how patients brain-activity patterns changed throughout the study. They found that as the trial went on, the brains of patients receiving the supplements started to shift from patterns typical of dementia to more normal patterns. Because EEG patterns reflect synaptic activity, this suggests that synaptic function increased following treatment, the researchers say.
Patients entering this study were in the early stages of Alzheimers disease, averaging around 25 on a scale of dementia that ranges from 1 to 30, with 30 being normal. A previous trial found that the supplement cocktail does not work in patients with Alzheimers at a more advanced stage. This makes sense, Wurtman says, because patients with more advanced dementia have probably already lost many neurons, so they cant form new synapses.
A two-year trial involving patients who dont have Alzheimers, but who are starting to show mild cognitive impairment, is now underway. If the drink seems to help, it could be used in people who test positive for very early signs of Alzheimers, before symptoms appear, Wurtman says. Such tests, which include PET scanning of the hippocampus, are now rarely done because there are no good Alzheimers treatments available.
Journal reference: Journal of Alzheimer's Disease
Provided by Massachusetts Institute of Technology
This story is republished courtesy of MIT News (web.mit.edu/newsoffice/), a popular site that covers news about MIT research, innovation and teaching.
- New approach to fighting Alzheimer's shows potential in clinical trial Jan 07, 2010 | not rated yet | 0
- Study points to cocktail therapy for Alzheimer's Jul 08, 2008 | not rated yet | 0
- MIT research offers new hope for Alzheimer's patients Apr 27, 2006 | not rated yet | 0
- 'Cocktail' of compounds improves brain function in rodents Nov 26, 2007 | not rated yet | 0
- Nationwide clinical trial of nutritional drink for Alzheimer's Jan 25, 2010 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
2 hours ago So energy can only be converted... So when you squeeze the bulb on a blood pressure cuff, you are applying kinetic energy. Then the cuff fills with...
How does momentum, inertia and drag affect the motion of an object?
4 hours ago How does momentum and inertia affect changes in speed, when considering acceleration from thrust, or from decelleration from drag? Say, for a...
What is Time-Varying Voltage?
5 hours ago In circuits, we have no problem saying that the voltage difference between two point is [itex]\cos(\omega t)[/itex], but what does that actually...
Contextual Relationships Between Momentum, Energy, and Force.
7 hours ago *I apologize in advance for the length of this post, if you wish to reduce reading skip to paragraph 5. Or if you are super lazy, the final...
Barometric pressure and the math behind it. Very interesting, I think.
9 hours ago Hey guys, I was actually researching the life of Edmond Halley and discovered that he discovered the relationship between barometric pressure and the...
Doubts in electrostatics
14 hours ago I have a few questions pertaining to some concepts in electrostatics, I'd be grateful if someone would help me out. 1) When we place a positive...
- More from Physics Forums - Classical Physics
More news stories
(Medical Xpress)—Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved ...
Alzheimer's disease & dementia 11 hours ago | 5 / 5 (2) | 0 |
(HealthDay)—Older individuals with nonmelanoma skin cancer (NMSC) seem to have a significantly reduced risk of developing Alzheimer's disease (AD), according to a study published online May 15 in Neurology.
Alzheimer's disease & dementia May 16, 2013 | 5 / 5 (1) | 0
People who have skin cancer may be less likely to develop Alzheimer's disease, according to new research published in the May 15, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology. The li ...
Alzheimer's disease & dementia May 15, 2013 | 5 / 5 (1) | 0 |
(Medical Xpress)—Scientists at Washington University School of Medicine in St. Louis have helped identify many of the biomarkers for Alzheimer's disease that could potentially predict which patients will develop the disorder ...
Alzheimer's disease & dementia May 14, 2013 | 3 / 5 (1) | 0 |
A drug developed by scientists at the Salk Institute for Biological Studies, known as J147, reverses memory deficits and slows Alzheimer's disease in aged mice following short-term treatment. The findings, ...
Alzheimer's disease & dementia May 13, 2013 | 4.2 / 5 (5) | 0 |
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
1 hour ago | not rated yet | 0
For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests
Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...
2 hours ago | not rated yet | 0 |
The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...
13 hours ago | not rated yet | 0 |
(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...
14 hours ago | 3.7 / 5 (3) | 0 |
In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...
11 hours ago | 3.7 / 5 (3) | 0 |
In order to avoid harms associated with alcohol consumption, in 2009 the National Institute on Alcohol Abuse and Alcoholism issued guidelines that define low-risk drinking. These guidelines differ for men and women: no more ...
11 hours ago | not rated yet | 0 |